Scarica l'app Stockscreener
19.67
0.05%
0.01
Dopo l'orario di chiusura:
19.66
-0.01
-0.05%
Silence Therapeutics Plc Adr Borsa (SLN) Ultime notizie
Why Is Silence Therapeutics Stock Skyrocketing Monday? - TradingView
Merck to Acquire Silence Therapeutics for $1.3 Billion - grafa.com
Merck KGaA agrees to buy Silence Therapeutics for roughly $1.1 billion - Briefs Finance
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany - FinancialContent
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany - Business Wire
Call options cover 1.5M shares in an amended stake report for Silence Therapeutics (SLN). - Stock Titan
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why - Zacks Investment Research
Silence Therapeutics at Cantor healthcare conference: divesiran advances By Investing.com - Investing.com South Africa
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Silence (SLN) Latest Quarter: The Report Provides a New Financial Snapshot for the Current Session; Investor Response: The Stock Gains 0.76% in Latest TradingEarnings Risk Report - dars.gov.et
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
What is HC Wainwright's Estimate for SLN Q3 Earnings? - MarketBeat
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEarnings Expansion Phase - careplusvn.com
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateRevenue Guidance Range - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateTech Earnings Analysis - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEstimate Revision Count - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEarnings Outlook Update - https://www.dars.gov.et/
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN) - MarketBeat
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com South Africa
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs - Business Wire
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Zacks Investment Research
Form 4: Griffiths Richard Ian reports acquisition/exercise transactions in SLN - Stock Titan
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentCore Business Growth - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentProfit Growth Outlook - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentMargin Expansion Trends - careplusvn.com
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentEarnings Forecast Report - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentRevenue Estimate Trend - dars.gov.et
Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics - Stock Titan
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - MarketBeat
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering - Business Wire
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - Yahoo Finance
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares - Business Wire
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - MarketBeat
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
2.02%
2.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):